GenSight: Goldman Sachs exceeds 5% threshold

(CercleFinance.com) - On November 6, The Goldman Sachs Group declared to the AMF that it had exceeded the thresholds of 5% of the capital and voting rights in GenSight Biologics and held, through Goldman Sachs International, 5.
50% of the capital and voting rights.

This crossing of thresholds resulted from an off-market acquisition of GenSight Biologics shares, for which the trading exemption no longer applies. Goldman Sachs International crossed the same thresholds individually.

Copyright (c) 2024 CercleFinance.com. All rights reserved.